Skip to main content
. 2025 Aug 4;7(1):e000361. doi: 10.1136/bmjsit-2024-000361

Table 2. Clinical outcomes.

Variables After the PS match
n=576
iMT TEVAR P value
n=480 n=96
Follow-up months 28.0 (15.0, 53.0) 31.0 (11.0, 50.5) 0.84
CT follow-ups / year 1.7 (1.1, 2.7) 1.8 (1.3, 2.4) 0.24
Death 19 4.0% 3 3.1% 0.70
Aortic events 70 14.6% 14 14.6% 1.00
Type-A AD 8 1.7% 1 1.0% 0.65
CVD 10 2.1% 1 1.0% 0.50
Paraplegia 6 1.3% 1 1.0% 0.87
VTE 180 37.5% 37 38.5% 0.85
IHD 57 11.9% 6 6.3% 0.11
CHF 105 21.9% 20 20.8% 0.82
CKD 68 14.2% 18 18.8% 0.25
DIC 96 20.0% 27 28.1% 0.08
Antiplatelets 136 28.3% 18 18.8% 0.05
Oral anticoagulants 82 17.1% 12 12.5% 0.27

Summary of patient outcomes in the PSM cohort (n=576), including follow-up duration, frequency of chest CT imaging, all-cause mortality, aortic-related events, and other complications. Summary in the crude cohort (n=4995) is summarized in Supplementary Table S5online supplemental table S5. Values are reported as medians with IQR for continuous variables and as counts with percentages for categorical variables.

Categorical values are reported as total numbers (%) and continuous variables as medians (IQR).

AD, aortic dissection; CHF, congestive heart failure; CKD, chronic kidney disease; CVD, cerebrovascular disease; DIC, disseminated intravascular coagulation; IHD, ischemic heart disease; iMT, initial medical therapy; PS, propensity score; PSM, PS matching; TEVAR, thoracic endovascular aortic repair; VTE, venous thromboembolism.